Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorEl, Cheikh, J.
dc.contributor.authorNgoya, M.
dc.contributor.authorGalimard, J.-E.
dc.contributor.authorReményi, P.
dc.contributor.authorKulagin, A.
dc.contributor.authorAljurf, M.
dc.contributor.authorMousavi, A.
dc.date.accessioned2025-01-12T18:55:07Z
dc.date.available2025-01-12T18:55:07Z
dc.date.issued2024
dc.identifier.issn0003-469X
dc.identifier.urihttps://doi.org/10.1038/s41409-024-02300-8
dc.identifier.urihttp://hdl.handle.net/11446/5059
dc.description.abstractT-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL. Using a large dataset from the European Society for Blood and Marrow Transplantation registry, we identified 1907 adult T-ALL patients (70% male) who underwent their first allo-HSCT in first complete remission (CR1) from matched sibling donors (MSD; 45%), unrelated donors (UD; 43%) or haploidentical donors (12%) between 2010 and 2021. The median age at transplant was 33.4 years (18.1–75). The median follow up was 2.9 years. Most patients underwent total body irradiation (TBI)-based myeloablative conditioning (69%). The 2-year overall survival (OS) was 69.4%, and leukemia -free survival (LFS) was 62.1%. In multivariate analysis, advanced age at transplant negatively affected LFS (for each 10-year increment, HR = 1.11, p = 0.004), GVHD-free, relapse-free survival (GRFS) (HR = 1.06, p = 0.04), OS (HR = 1.12, p = 0.002), and non-relapse mortality (NRM) (HR = 1.23, p < 0.001). More recent years of allo-HSCT were associated with improved GFRS (For each 3-year increment, HR = 0.89, p < 0.001), OS (HR = 0.9, p = 0.02), and decreased NRM (HR = 0.82, p = 0.008). TBI improved LFS. (HR = 0.79, p = 0.02), GRFS (HR = 0.83, p = 0.04), and relapse incidence (RI) (HR = 0.65, p < 0.001). Female-to-male transplant negatively affected GRFS (HR = 1.21, p = 0.02) and OS (HR = 1.23, p = 0.048). In vivo T-cell depletion significantly improved GFRS (HR = 0.74, p < 0.001). This large study identified prognostic factors, such as age at transplant conditioning regimen, in influencing post-transplant in adult T-ALL patients undergoing allo-HSCT. Importantly, a significant improvement over time was noted. These findings hold great promise for new adapted treatment strategies and can serve as a benchmark for future studies in that setting. © The Author(s), under exclusive licence to Springer Nature Limited 2024.en_US
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.identifier.doi10.1038/s41409-024-02300-8
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectFemaleen_US
dc.subjectHematopoietic Stem Cell Transplantationen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPrecursor T-Cell Lymphoblastic Leukemia-Lymphomaen_US
dc.subjectPrognosisen_US
dc.subjectRegistriesen_US
dc.subjectSurvival Rateen_US
dc.subjectTransplantation Conditioningen_US
dc.subjectYoung Adulten_US
dc.subjectalemtuzumaben_US
dc.subjectcyclophosphamideen_US
dc.subjectcyclosporineen_US
dc.subjectglobulinen_US
dc.subjectmethotrexateen_US
dc.subjectmycophenolate mofetilen_US
dc.subjectacute leukemiaen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectallogeneic hematopoietic stem cell transplantationen_US
dc.subjectArticleen_US
dc.subjectbone marrowen_US
dc.subjectchronic graft versus host diseaseen_US
dc.subjectCytomegalovirusen_US
dc.subjectdisease free survivalen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjectgraft versus host reactionen_US
dc.subjecthematopoietic stem cell transplantationen_US
dc.subjecthumanen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmortalityen_US
dc.subjectoutcome assessmenten_US
dc.subjectoverall survivalen_US
dc.subjectprognosisen_US
dc.subjectrecurrence free survivalen_US
dc.subjectT cell acute lymphoblastic leukemiaen_US
dc.subjectadolescenten_US
dc.subjecthematopoietic stem cell transplantationen_US
dc.subjectmiddle ageden_US
dc.subjectproceduresen_US
dc.subjectprognosisen_US
dc.subjectregisteren_US
dc.subjectsurvival rateen_US
dc.subjectT cell acute lymphoblastic leukemiaen_US
dc.subjecttherapyen_US
dc.subjecttransplantation conditioningen_US
dc.subjectyoung adulten_US
dc.titlePrognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working partyen_US
dc.typearticleen_US
dc.departmentDBÜen_US
dc.identifier.issue9en_US
dc.identifier.volume59en_US
dc.identifier.startpage1239en_US
dc.identifier.endpage1246en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempEl Cheikh J., Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Ngoya M., EBMT Statistical Unit, Saint Antoine Hospital, Sorbonne University, Paris, France; Galimard J.-E., EBMT Statistical Unit, Saint Antoine Hospital, Sorbonne University, Paris, France; Reményi P., Dél-pesti Centrumkórház –Országos Hematológiai és Infektológiai Intézet, Dept. Haematology and Stem Cell Transplant, Albert—Budapest, Budapest, Hungary; Kulagin A., RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation; Aljurf M., King Faisal Specialist Hospital & amp; Research Centre, Oncology (Section of Adult Haematolgy/BMT)—Riyadh, Riyadh, Saudi Arabia; Mousavi A., Shariati Hospital, Hematology-Oncology and BMT Research—Teheran, Tehran, Iran; Wu D., First Affiliated Hospital of Soochow University, Department of Hematology—Suzhou, Suzhou, China; Ozcelik T., Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Hematopoietic SCT, Unit—Istanbul, İstanbul, Turkey; Salmenniemi U., HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit—Helsinki, Helsinki, Finland; Castilla-Llorente C., Gustave Roussy Cancer Campus, BMT Service, Deen_US
dc.identifier.pmid38834689en_US
dc.identifier.scopus2-s2.0-85195171247en_US
dc.authorscopusid57190088309
dc.authorscopusid57226109363
dc.authorscopusid57189886743
dc.authorscopusid6603458868
dc.authorscopusid57788890000
dc.authorscopusid55863021500
dc.authorscopusid57222718733


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster